28 completed, 15 terminated, 12 recruiting, 5 withdrawn. 33 Phase 2, 25 Phase 1, 4 Phase 3, 3 Not applicable, 1 Early Phase 1.
Follow Blood Component Removal: new trials by email Literature Review of Blood Component Removal trials Research Report on Blood Component Removal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma Cyclophosphamide, Fludarabine, Mesna - Pediatric Osteosarcoma | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 41 | 2026-09-01 | 2026-09-01 |
| A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation - Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 46 | 2026-05-08 | 2026-07-28 |
| Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia Autologous Anti-CD19/CD20/CD22 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration - Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | Ohio State University Comprehensive Cancer Center | 24 | 2026-01-14 | 2026-08-26 |
| Ex Vivo Expansion (ACT-X) Blood Draw, Apheresis - Solid Tumor, Healthy | Recruiting | Mayo Clinic | 24 | 2025-12-16 | 2026-06-09 | |
| Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial Acetaminophen, Biospecimen Collection, Dexamethasone - Multiple Myeloma | Phase 4 | Recruiting | Emory University | 94 | 2025-09-24 | 2026-07-23 |
| Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Undifferentiated Leukemia | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 36 | 2025-09-23 | 2026-05-15 |
| Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas Anti-GARP Chimeric Antigen Receptor-T Cells, Biospecimen Collection, Chest Radiography - Recurrent Malignant Glioma, Recurrent WHO Grade 3 Glioma | Phase 1 | Recruiting | Ohio State University Comprehensive Cancer Center | 30 | 2025-05-21 | 2026-05-08 |
| Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma Leukapheresis, Bridging Therapy, Lymphodepletion - B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent | Phase 2 | Terminated | Universität Münster | 1 | 2025-03-13 | 2025-09-04 |
| FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia FOLR1 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Childhood Acute Myeloid Leukemia, Refractory Childhood Acute Myeloid Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 12 | 2025-02-24 | 2026-08-06 |
| CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Granulocyte Colony-Stimulating Factor - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 216 | 2024-07-12 | 2026-03-10 |
| Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder G-CSF (filgrastim or biosimilar), Apheresis, Plerixafor - RUNX1 Familial Platelet Disorder | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 4 | 2024-05-20 | 2026-06-11 |
| Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma Apheresis, Autologous Stem Cell Transplantation, CAR-T Cell Therapy - Lymphoma, B-Cell, Autologous Stem Cell Transplantation | Phase 2 | Terminated | The First Affiliated Hospital of Soochow University | 8 | 2024-01-01 | 2026-06-05 |
| Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Biopsy, Biospecimen Collection, Computed Tomography - Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 38 | 2023-09-28 | 2026-09-21 |
| Biological Variables Affecting CD34+ Peripheral Cells Collection Efficiency apheresis procedure - Optimize PBSC Harvest Through Automated Buffy Coat | Completed | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 113 | 2023-09-01 | 2024-03-13 | |
| Immunoadsorption vs. Sham Treatment in Post COVID-19 Patients With Chronic Fatigue Syndrome Immunoadsorption vs. sham immunoadsorption - Fatigue, Post-Acute COVID-19 Syndrome | Not applicable | Completed | Hannover Medical School | 63 | 2023-08-15 | 2025-09-15 |
| Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation Biopsy, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia | Phase 2 | Active not recruiting | City of Hope Medical Center | 9 | 2023-06-02 | 2026-10-01 |
| Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate - Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Sumithira Vasu | 54 | 2022-06-30 | 2026-05-29 |
| A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion Bone Marrow mobilization, Apheresis, MNV-BM-PLC infusion - Primary Mitochondrial Diseases | Phase 1 | Withdrawn | Minovia Therapeutics Ltd. | 2022-03-01 | 2025-06-22 | |
| Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing Apheresis, Next Generation Sequencing (NGS), Long Range NGS HLA typing - Solid Tumor, Adult, Colorectal Cancer | Recruiting | A2 Biotherapeutics Inc. | 500 | 2021-10-29 | 2026-09-25 | |
| Liver Transplantation With Tregs at UCSF arTreg, leukapheresis, cyclophosphamide - Liver Transplant | Phase 1 / Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 42 | 2021-04-22 | 2024-04-23 |
Showing 20 of 64. Sign in to see all of them.
Multiple Myeloma (11) · Lymphoma, Non-Hodgkin (9) · Lymphoma (6) · Hodgkin Disease (5) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Leukemia, Myeloid, Acute (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Myelodysplastic Syndromes (4) · Carcinoma, Non-Small-Cell Lung (3) · Glioma (3) · Leukemia (3) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Melanoma (3) · Neoplasms, Plasma Cell (3) · Burkitt Lymphoma (2)
M.D. Anderson Cancer Center (10) · National Cancer Institute (NCI) (6) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · City of Hope Medical Center (4) · Mayo Clinic (4) · St. Jude Children's Research Hospital (3) · Washington University School of Medicine (3) · Emory University (2) · Fred Hutchinson Cancer Center (2) · Macarena De La Fuente, MD (2) · Ohio State University Comprehensive Cancer Center (2) · The First Affiliated Hospital of Soochow University (2) · A2 Biotherapeutics Inc. (1) · Amgen (1) · Assistance Publique - Hôpitaux de Paris (1)
United States (50) · Germany (3) · Italy (3) · China (2) · France (2) · Australia (1) · Canada (1) · Czechia (1) · Israel (1) · Netherlands (1) · Russia (1) · Spain (1) · United Kingdom (1)
Chitra M. Hosing, MD (2) · Sumithira Vasu, MD (2) · Amanda F. Cashen, M.D. (1) · Camille Abboud, M.D. (1) · Chitra Hosing (1) · Chitra Hosing, MD (1) · Daniel H Fowler, M.D. (1) · Deipei Wu, M.D. (1) · Edward Ziga, MD (1) · Elizabeth J. Shpall, MD (1) · Eric W Ng, MD, FAAP (1) · Eva Rombout, MD (1) · Georg Lenz, Prof (1)
PMID 19569973, PMID 19667400, PMID 20661232, PMID 21386997, PMID 22282683, PMID 22555974, PMID 23357149, PMID 24429337, PMID 25936321, PMID 27213629, PMID 28797783, PMID 29096833, PMID 29403531, PMID 31324444, PMID 31940591, PMID 34687939, PMID 34889384, PMID 34980909, PMID 35115306, PMID 35605184, PMID 36450385, PMID 37486616, PMID 38376944, PMID 40873341, PMID 41918932, PMID 42248607, PMID 42500906
P30CA033572 (3), 2015 (1), P30CA138292 (1), R01CA266783 (1), R01CA274985 (1), R01CA276313 (1), R01CA276374 (1), R01CA294704 (1), U01AI063594 (1), U01AI077867 (1), UM1AI109565 (1)